Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France and currently employs 180 full-time employees. The company went IPO on 2006-12-19. The firm provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The firm leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
Follow-Up Questions
What is the price performance of GNFT stock?
The current price of GNFT is $4.33, it has decreased 1.19% in the last trading day.
What are the primary business themes or industries for Genfit SA?
Genfit SA belongs to Biotechnology industry and the sector is Health Care
What is Genfit SA market cap?
Genfit SA's current market cap is $216.5M
Is Genfit SA a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for Genfit SA, including 8 strong buy, 4 buy, 1 hold, 0 sell, and 8 strong sell
